Biochemical mechanisms of mineralization disorders and their correction in rats with maxillary microimplants against the background of toxic hepatitis

Annotation. Dental implantation has recently become a primary method for treating complete or partial edentulousness of the upper and lower jaws. This procedure involves placing artificial titanium structures in the position of lost teeth. One of the key requirements for dental implantation is good jawbone mineral density and proper biochemical indicators of liver function and mineral metabolism, which may be impaired in liver pathology. The aim of our study was to investigate biochemical markers of hepatobiliary system function in rats with maxillary microimplants under pharmacological correction of toxic hepatitis. The rats were divided into four groups: control group – 7 rats with a microimplant placed at the site of an extracted upper tooth; еxperimental group 1 – 7 rats with a microimplant placed at the site of an extracted upper tooth against the background of toxic hepatitis; еxperimental group 2 – 7 rats with a microimplant placed at the site of an extracted upper tooth against the background of toxic hepatitis, treated with ursodeoxycholic acid according to a specified regimen; еxperimental group 3 – 7 rats with a microimplant placed at the site of an extracted upper tooth against the background of toxic hepatitis, treated with ursodeoxycholic acid and osteogenon according to a specified regimen. All rats underwent biochemical analysis for liver disease markers, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGT), alkaline phosphatase (ALP), and total bilirubin. To assess jawbone mineral density disorders in the experiment, biochemical markers of bone metabolism were analyzed, specifically the activity of alkaline phosphatase, acid phosphatase, free hydroxyproline, and the pro-inflammatory cytokine IL-1β. The obtained data reliably indicate the negative impact of chronic toxic hepatitis on bone tissue metabolism (p<0.05). However, it has been conclusively proven that the combined use of ursodeoxycholic acid and osteogenon improves bone metabolism (p<0.05), which positively influences the integration of microimplants.